Adverum Biotechnologies Inc (NAS:ADVM)
$ 8.75 -0.18 (-2.02%) Market Cap: 181.62 Mil Enterprise Value: 163.87 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript

Nov 14, 2020 / 03:30PM GMT
Operator

Greetings, and welcome to the Adverum Biotechnologies Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to hand this call over to Ms. Myesha Lacy, Vice President of Investor Relations and Corporate Communications for Adverum. Please go ahead.

Myesha Lacy
Adverum Biotechnologies, Inc. - VP of IR & Corporate Communications

Good morning, and welcome to the Adverum Biotechnologies conference call. Today, we issued a press release to share new data from our OPTIC Phase I clinical trial of ADVM-022 in wet AMD. A copy of this announcement is available on the press releases page of the Investor Relations section of our corporate website at www.adverum.com. Please note that a replay of today's call and a copy of today's slide presentation, with the exception of Dr. Steven Yeh's slides, will also be available for download on the Events and Presentations section of our website.

Joining me today is Dr. Laurent Fischer, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot